Rupinder Kaur Gill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rupinder Kaur Gill has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Jitender Bariwal
Department of Pharmaceutical Chemistry
7 shared publications Gagandeep Singh
Department of Chemistry, Indian Institute of Technology Ropar- 140001 Punjab India
3 shared publicationsRamandeep Kaur
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga-142001, India
3 shared publicationsGurneet Kaur
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga 142001, Punjab, India
2 shared publicationsJitender Bariwal
Department of Pharmaceutical Chemistry, ISF college of Pharmacy, Moga-142001, Punjab, India
2 shared publicationsNishu Singla
I.K. Gujral Punjab Technical University Kapurthala, Jalandhar 144 601 Punjab India
2 shared publications
Latest Publications
- Open Access
- 1 April 2020
- Published by Wiley in ChemistrySelect
- Vol. 5 (13) , 3835-3842
Design, Synthesis and Antimicrobial Evaluation of 1,3,4‐Oxadiazole/1,2,4‐Triazole‐Substituted Thiophenes
The increasing level of antimicrobial resistance in pathogenic bacteria, together with the lack of new potential drug scaffolds in the pipeline, make the problem of infectious diseases a major public health concern. Thus, in this context, a novel series of 1,3,4‐oxadiazole‐substituted thiophenes ( 4 a – m ) and 1,2,4‐triazole ( 6 a – m ) substituted thiophene derivatives were synthesized. Characterization of all the synthesized derivatives was done by various spectroscopic techniques such as 1 H NMR, 13 C NMR spectroscopy and mass spectrometry, and evaluated for antimicrobial activity against various pathological strains using broth dilution and disc diffusion method. In particular, compound 6 e and 4 e exhibited significant inhibitory potential with MIC ranging from 2–7 μg mL −1 against S. aureus , B. subtilis , P. aeruginosa and E. coli . Additionally, compound 6 e was found to be highly potent against methicillin resistant S. aureus (MRSA; MIC=2 μg mL −1 ). Molecular docking studies were also performed to confer the possible mode of action and association studies indicate the binding of potent active compound with DHFR enzyme (K a =2.10×10 3 M −1 ). Further, the mechanism of action has also been explored by atomic force microscopy (AFM), which reveals the bacterial cell wall deformity and cell wall rupturing that may lead to bacteria cell death. Additionally, in silico ADME prediction study suggested the drug like properties of active compounds.
- 1 April 2020
- Published by Wiley in ChemistrySelect
- Vol. 5 (13) , 3835-3842
Open AccessDesign, Synthesis and Antimicrobial Evaluation of 1,3,4‐Oxadiazole/1,2,4‐Triazole‐Substituted Thiophenes
The increasing level of antimicrobial resistance in pathogenic bacteria, together with the lack of new potential drug scaffolds in the pipeline, make the problem of infectious diseases a major public health concern. Thus, in this context, a novel series of 1,3,4‐oxadiazole‐substituted thiophenes ( 4 a – m ) and 1,2,4‐triazole ( 6 a – m ) substituted thiophene derivatives were synthesized. Characterization of all the synthesized derivatives was done by various spectroscopic techniques such as 1 H NMR, 13 C NMR spectroscopy and mass spectrometry, and evaluated for antimicrobial activity against various pathological strains using broth dilution and disc diffusion method. In particular, compound 6 e and 4 e exhibited significant inhibitory potential with MIC ranging from 2–7 μg mL −1 against S. aureus , B. subtilis , P. aeruginosa and E. coli . Additionally, compound 6 e was found to be highly potent against methicillin resistant S. aureus (MRSA; MIC=2 μg mL −1 ). Molecular docking studies were also performed to confer the possible mode of action and association studies indicate the binding of potent active compound with DHFR enzyme (K a =2.10×10 3 M −1 ). Further, the mechanism of action has also been explored by atomic force microscopy (AFM), which reveals the bacterial cell wall deformity and cell wall rupturing that may lead to bacteria cell death. Additionally, in silico ADME prediction study suggested the drug like properties of active compounds.
- 23 January 2019
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 10 (3) , 421-430
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition
In the present work, coumarin based pyrazolines (7a–g) have been synthesized and investigated for their in vitro and in vivo anti-inflammatory potential. Amongst the synthesized compounds, compounds 7a, 7d and 7f exhibited significant in vitro anti-inflammatory activity as compared to the standard etoricoxib. Keeping this in mind, in vivo investigations were carried out via carrageenan induced inflammation and acetic acid induced writhing models in male Wistar rats and compound 7a was found to possess appreciable anti-inflammatory and analgesic potential. The mode of action of compound 7a was also investigated by using substance P as the biomarker, which shows promising results. Further, the selectivity of the most active compound 7a against the cyclooxygenase enzyme was supported by molecular docking studies which reveal that compound 7a has greater binding affinity towards COX-2 over COX-1 and 5-LOX enzymes. In silico ADME analysis of compound 7a confirms the drug-like characteristics and the in vivo acute toxicity study showed the safety of the compound even up to a 2000 mg kg−1 dose. Thus, compound 7a was identified as an effective anti-inflammatory agent, and can be explored for further analgesic/anti-inflammatory drug design and development.
- 23 January 2019
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 10 (3) , 421-430
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition
In the present work, coumarin based pyrazolines (7a–g) have been synthesized and investigated for their in vitro and in vivo anti-inflammatory potential. Amongst the synthesized compounds, compounds 7a, 7d and 7f exhibited significant in vitro anti-inflammatory activity as compared to the standard etoricoxib. Keeping this in mind, in vivo investigations were carried out via carrageenan induced inflammation and acetic acid induced writhing models in male Wistar rats and compound 7a was found to possess appreciable anti-inflammatory and analgesic potential. The mode of action of compound 7a was also investigated by using substance P as the biomarker, which shows promising results. Further, the selectivity of the most active compound 7a against the cyclooxygenase enzyme was supported by molecular docking studies which reveal that compound 7a has greater binding affinity towards COX-2 over COX-1 and 5-LOX enzymes. In silico ADME analysis of compound 7a confirms the drug-like characteristics and the in vivo acute toxicity study showed the safety of the compound even up to a 2000 mg kg−1 dose. Thus, compound 7a was identified as an effective anti-inflammatory agent, and can be explored for further analgesic/anti-inflammatory drug design and development.
- 1 March 2018
- Published by Springer Nature in Chemistry of Heterocyclic Compounds
- Vol. 54 (3) , 241-248
Gold and silver nanoparticle-catalyzed synthesis of heterocyclic compounds
- 1 March 2018
- Published by Springer Nature in Chemistry of Heterocyclic Compounds
- Vol. 54 (3) , 241-248
Gold and silver nanoparticle-catalyzed synthesis of heterocyclic compounds
- 28 April 2017
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 17 (5) , 701-711
Design and Green Synthesis of Thieno[2,3-d]pyrimidine Analogues as Potential Antiproliferative Agents
- 28 April 2017
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 17 (5) , 701-711
Design and Green Synthesis of Thieno[2,3-d]pyrimidine Analogues as Potential Antiproliferative Agents
- 11 August 2016
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 16 (14) , 1134-1166
Review on EGFR Inhibitors: Critical Updates
Epidermal Growth Factor Receptor (EGFR) is a transmembrane glycoprotein that constitutes one of the four members of ErbB family of tyrosine kinase receptors. Activation of EGFR leads to autophosphorylation of receptor tyrosine kinase that initiates a cascade of downstream signaling pathways involved in regulating cellular proliferation, differentiation, and survival. EGFR is abnormally activated by various mechanisms like receptor overexpression, mutation, ligand-dependent receptor dimerization, ligand-independent activation and is associated with the development of variety of human cancers. EGFR inhibition is one of the key targets for cancer chemotherapy. Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of non-small cell lung cancer led to tremendous development of novel EGFR inhibitors in the last decade. Diverse class of chemical compounds from the synthetic origin has been extensively studied. This review highlights the various classes of synthetically derived molecules which have been reported in the last few years as potential EGFR and EGFR/ErbB-2 dual inhibitors. A brief synthetic methodology to access these compounds has been highlighted along with the SAR. We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compounds that inhibit EGFR and ErbB-2.
- 11 August 2016
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 16 (14) , 1134-1166
Review on EGFR Inhibitors: Critical Updates
Epidermal Growth Factor Receptor (EGFR) is a transmembrane glycoprotein that constitutes one of the four members of ErbB family of tyrosine kinase receptors. Activation of EGFR leads to autophosphorylation of receptor tyrosine kinase that initiates a cascade of downstream signaling pathways involved in regulating cellular proliferation, differentiation, and survival. EGFR is abnormally activated by various mechanisms like receptor overexpression, mutation, ligand-dependent receptor dimerization, ligand-independent activation and is associated with the development of variety of human cancers. EGFR inhibition is one of the key targets for cancer chemotherapy. Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of non-small cell lung cancer led to tremendous development of novel EGFR inhibitors in the last decade. Diverse class of chemical compounds from the synthetic origin has been extensively studied. This review highlights the various classes of synthetically derived molecules which have been reported in the last few years as potential EGFR and EGFR/ErbB-2 dual inhibitors. A brief synthetic methodology to access these compounds has been highlighted along with the SAR. We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compounds that inhibit EGFR and ErbB-2.
- 21 July 2016
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 7 (10) , 1966-1972
Design and microwave assisted synthesis of novel 2-phenyl/2-phenylethynyl-3-aroyl thiophenes as potent antiproliferative agents
In the present study, 2-phenyl/2-phenylethynyl-3-aroyl thiophenes have been designed and evaluated as antiproliferative agents. The significant antiproliferative potential of compounds 12j and 14h were might be attributed to their potential to induce cell cycle arrest at G 2 /M phase.
- 21 July 2016
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 7 (10) , 1966-1972
Design and microwave assisted synthesis of novel 2-phenyl/2-phenylethynyl-3-aroyl thiophenes as potent antiproliferative agents
In the present study, 2-phenyl/2-phenylethynyl-3-aroyl thiophenes have been designed and evaluated as antiproliferative agents. The significant antiproliferative potential of compounds 12j and 14h were might be attributed to their potential to induce cell cycle arrest at G 2 /M phase.
- Open Access
- 24 February 2016
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 10 (1) , 38
Diabetic ketoacidosis presenting with atypical hemolytic uremic syndrome associated with a variant of complement factor B in an adult: a case report
Non-Shiga toxin-associated hemolytic uremic syndrome is known to be caused by dysregulation of the alternative complement pathway. Infections, drugs, pregnancy, bone marrow transplantation, malignancy, and autoimmune disorders have all been reported to trigger episodes of atypical hemolytic uremic syndrome. To the best of our knowledge, there have been no previous reports of an association between diabetic ketoacidosis and atypical hemolytic uremic syndrome. We describe a case of a 26-year-old Spanish man who presented with diabetic ketoacidosis and was found to have the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The patient had a normal ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity level, and his renal biopsy demonstrated predominant changes of diabetic glomerulosclerosis with an area compatible with thrombotic microangiopathy suggestive of superimposed atypical hemolytic uremic syndrome. Complement sequencing subsequently revealed a potential causative mutation in exon 12 of complement factor B with changes of lysine at amino acid position 533 to an arginine (CFB p.K533R). To the best of our knowledge, this is the first case report of diabetic ketoacidosis presenting with atypical hemolytic uremic syndrome associated with a variant of complement factor B in an adult patient.
- 24 February 2016
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 10 (1) , 38
Open AccessDiabetic ketoacidosis presenting with atypical hemolytic uremic syndrome associated with a variant of complement factor B in an adult: a case report
Non-Shiga toxin-associated hemolytic uremic syndrome is known to be caused by dysregulation of the alternative complement pathway. Infections, drugs, pregnancy, bone marrow transplantation, malignancy, and autoimmune disorders have all been reported to trigger episodes of atypical hemolytic uremic syndrome. To the best of our knowledge, there have been no previous reports of an association between diabetic ketoacidosis and atypical hemolytic uremic syndrome. We describe a case of a 26-year-old Spanish man who presented with diabetic ketoacidosis and was found to have the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The patient had a normal ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity level, and his renal biopsy demonstrated predominant changes of diabetic glomerulosclerosis with an area compatible with thrombotic microangiopathy suggestive of superimposed atypical hemolytic uremic syndrome. Complement sequencing subsequently revealed a potential causative mutation in exon 12 of complement factor B with changes of lysine at amino acid position 533 to an arginine (CFB p.K533R). To the best of our knowledge, this is the first case report of diabetic ketoacidosis presenting with atypical hemolytic uremic syndrome associated with a variant of complement factor B in an adult patient.
- 28 August 2015
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 53 (5) , 1519-1527
Synthesis, Cytotoxic Evaluation, and In Silico Studies of 4‐Substituted Coumarins
Two series of coumarins possessing the aniline‐ and heterocyclic ring at 4th position have been synthesized and evaluated for their in vitro cytotoxic activity against MCF‐7 cancer cell line in MTT assay. Structure activity relationship (SAR) studies reveal that the electron donor group at position‐8 of coumarin played an important role in cytotoxic activity. Compound VIId showed the potent cytotoxic activity followed by compound Xa with IC50 = 6.25 and 6.50 μM, respectively. A docking study has also been carried out for the most potent compound to get an insight into molecular interactions with p50 subunit of NF‐κB protein.
- 28 August 2015
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 53 (5) , 1519-1527
Synthesis, Cytotoxic Evaluation, and In Silico Studies of 4‐Substituted Coumarins
Two series of coumarins possessing the aniline‐ and heterocyclic ring at 4th position have been synthesized and evaluated for their in vitro cytotoxic activity against MCF‐7 cancer cell line in MTT assay. Structure activity relationship (SAR) studies reveal that the electron donor group at position‐8 of coumarin played an important role in cytotoxic activity. Compound VIId showed the potent cytotoxic activity followed by compound Xa with IC50 = 6.25 and 6.50 μM, respectively. A docking study has also been carried out for the most potent compound to get an insight into molecular interactions with p50 subunit of NF‐κB protein.
- 12 February 2015
- Published by Wiley in Archiv der Pharmazie
- Vol. 348 (3) , 155-178
Recent Advances in the Chemistry and Biology of Benzothiazoles
Benzothiazole is a privileged heterocyclic scaffold having a benzene ring fused with a five‐membered thiazole ring. This moiety has attracted considerable attention because of its wide range of pharmacological activities such as antitubercular, antimicrobial, antimalarial, anticonvulsant, anthelmintic, analgesic, anti‐inflammatory, antidiabetic, antitumor activity, etc. In the last few years, some novel benzothiazoles have been developed with varied biological activities. To access this scaffold in high yield and to introduce diversity, a variety of new synthetic methods have been invented. In this review, we highlight the development of novel benzothiazoles for various biological activities along with the best synthetic protocols for their synthesis.
- 12 February 2015
- Published by Wiley in Archiv der Pharmazie
- Vol. 348 (3) , 155-178
Recent Advances in the Chemistry and Biology of Benzothiazoles
Benzothiazole is a privileged heterocyclic scaffold having a benzene ring fused with a five‐membered thiazole ring. This moiety has attracted considerable attention because of its wide range of pharmacological activities such as antitubercular, antimicrobial, antimalarial, anticonvulsant, anthelmintic, analgesic, anti‐inflammatory, antidiabetic, antitumor activity, etc. In the last few years, some novel benzothiazoles have been developed with varied biological activities. To access this scaffold in high yield and to introduce diversity, a variety of new synthetic methods have been invented. In this review, we highlight the development of novel benzothiazoles for various biological activities along with the best synthetic protocols for their synthesis.
- 1 November 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 87, 89-124
Recent developments in tubulin polymerization inhibitors: An overview
- 1 November 2014
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 87, 89-124
Recent developments in tubulin polymerization inhibitors: An overview